1. Home
  2. GLV vs ANIX Comparison

GLV vs ANIX Comparison

Compare GLV & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clough Global Dividend and Income Fund of beneficial interest

GLV

Clough Global Dividend and Income Fund of beneficial interest

HOLD

Current Price

$6.39

Market Cap

77.2M

Sector

Finance

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.67

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLV
ANIX
Founded
N/A
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.2M
88.8M
IPO Year
2004
2013

Fundamental Metrics

Financial Performance
Metric
GLV
ANIX
Price
$6.39
$2.67
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
44.8K
99.1K
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.48
$2.44
52 Week High
$6.42
$5.46

Technical Indicators

Market Signals
Indicator
GLV
ANIX
Relative Strength Index (RSI) 66.25 42.11
Support Level $5.83 $2.65
Resistance Level N/A $3.12
Average True Range (ATR) 0.07 0.12
MACD 0.01 -0.02
Stochastic Oscillator 91.43 23.81

Price Performance

Historical Comparison
GLV
ANIX

About GLV Clough Global Dividend and Income Fund of beneficial interest

Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: